

# БИОЛОГИЧЕСКИЕ НАУКИ

## BIOLOGICAL SCIENCES

UDK 575:576.8.06/0973  
BBK 28.041  
Б 71

**Hubert E. Blum**

*Doctor of Medicine, Professor of Medicine, Department of Medicine II, University Hospital Freiburg, Freiburg, Germany, e-mail: hubert.blum@uniklinik-freiburg.de*

### **The microbiome: key player in human health and disease.**

**Review article**

*(Peer-reviewed)*

**Abstract.** *Until recently, human microbiology was based on the identification of single microbes, such as bacteria, fungi and viruses, frequently isolated from patients with acute or chronic infections. Novel culture-independent molecular biochemical analyses (genomics, transcriptomics, proteomics, metabolomics) allow today to detect and classify the diverse microorganisms in a given ecosystem (microbiota), such as the gastrointestinal tract, the skin, the airway system, the urogenital tract and others, and to assess all genomes in these ecosystems (microbiome) as well as their gene products. These analyses revealed that each individual has its own microbiota that plays a role in health and disease. In addition, they greatly contributed to the recent advances in the understanding of the pathogenesis of a wide range of human diseases. It is to be expected that these new insights will translate into diagnostic, therapeutic and preventive measures in the context of personalized/precision medicine.*

**Keywords:** *microbiota, fecal transplantation, inflammatory bowel disease, obesity, atherosclerosis, neurodegenerative diseases.*

**Хуберт Е. Блюм**

*Доктор медицинских наук, профессор медицины медицинского факультета II клиники университета Фрайбурга, Фрайбург, Германия, e-mail: hubert.blum@uniklinik-freiburg.de*

### **Микробиом: важнейший фактор в поддержании здоровья и в возникновении болезни человека.**

**Обзорная статья**

*(Рецензирована)*

**Аннотация.** *До недавнего времени микробиология человека базировалась на идентификации отдельных микроорганизмов, таких как бактерии, грибы и вирусы, изолированных часто от пациентов с острыми или хроническими инфекциями. Новые, независимые от культуры молекулярные биохимические исследования по геномике, транскриптомике, протеомике, метаболомике позволяют сегодня обнаружить и классифицировать разнообразные микроорганизмы в определенных экосистемах (микробиотах), таких как желудочно-кишечный тракт, кожа, система дыхательных путей, мочеполовая система и другие, и оценить все геномы в этих экосистемах (микробиомах), а также их генные продукты. Эти исследования показали, что у каждого человека есть своя собственная микробиота, которая играет значительную роль в поддержании здоровья и в возникновении болезни. Кроме того, эти исследования значительно способствовали недавним достижениям в понимании патогенеза широкого спектра человеческих болезней. Нужно ожидать, что эти новые представления будут транслированы в диагностические, терапевтические и превентивные меры в контексте персонализированной медицины / медицины точности.*

**Ключевые слова:** *микробиоматерия, фекальная трансплантация, воспалительное заболевание кишечника, ожирение, атеросклероз, нейродегенеративные заболевания.*

## **1. Introduction**

The basic aspects of molecular and cell biology are not only integral part of biomedical research but are also translated into patient care. Several global consortia have been launched and in part completed during the last decades. All of them continuously transform basic biomedical research and translate into medical applications and, after evaluation in randomized clinical trials, enter clinical practice with a tremendous potential to advance the diagnosis, treatment and prevention of human diseases.

More than 15 years ago, the international human genome organization (HUGO) project established the complete sequence of the ca. 3 billion base pairs that make up the human genome. In or-

der to utilize these data from the HUGO project for research as well as for clinical applications and to define the functions of newly identified genes, collectively termed “functional genomics”, strategies were developed to globally analyze genomic DNA sequences as well as their cell-, tissue- or organ-specific expression profile. Using chips, so-called “microarrays”, thousands or ten thousands of single-stranded DNA species, reverse transcribed RNA (cDNA) or oligonucleotides of known sequence can provide a global gene (genomics), gene expression (transcriptomics, proteomics) or metabolite (metabolomics) profile (“signature”) that is characteristic for the disease of individual patients, including its natural course/prognosis and response to therapy.

In 2005 the international haplotype map (HapMap) project was initiated to identify, based on genome-wide association studies (GWAS) in ethnically different populations, single nucleotide polymorphisms (SNPs) and their association with specific human diseases and individual phenotypic characteristics, respectively. Through GWAS an increasing number of gene loci have been identified that are associated with individual (future) phenotypic traits, such as hair or eye color, height, body mass index and others as well as with the disposition to develop a specific disease [1]. Further, genetic variants are associated with the individuals’ response to drug treatment, e.g., to lithium [2]. Overall, GWAS allow an increasingly better understanding of disease pathogenesis and a more accurate assessment of the individual risk to develop a specific disease. Clinically, this may eventually translate into clinical advances in disease prevention, early diagnosis and therapy. It should be cautioned, however, that the contribution of a defined SNP to the risk assessment for a given disease must be weighed against established clinical parameters and needs to be carefully evaluated before entering clinical practice.

## 2. Review

### 2.1. The Human Microbiome Project

The human microbiome project (HMP) was established in 2007 as another global consortium [3]. The HMP and the “Metagenomics of the Human Intestinal Tract (Meta-HiT) Consortium Europe” aim at the sequencing of all microbes (eukaryotes, archaea, bacteria, viruses) that inhabit specific body sites, such as the mouth, throat and airways, stomach and intestine, the urogenital system and the skin, respectively. Recent data demonstrate that specific compositions of the microbial community are associated with health and disease and suggest that the detailed characterization, function and variation of the microbial community will reveal important commensal host-microbe as well as microbe-microbe interactions with diagnostic, therapeutic and preventive implications [4, 5].

While the HMP has meanwhile developed into a major field of biomedical research, the intestinal microbial community in particular has turned out to play a major role in human health and disease pathogenesis as will be discussed in more detail below [6].

### 2.2. The intestinal microbial community

In recent years the intestinal microbial community has been studied in great detail. It represents a microbial ecosystem consisting of trillion microbial cells with an aggregate 9.9 million microbial genes across the fecal microbiome [7]. While until recently, the environment *in utero* has been considered sterile, DNA-based analyses identified bacterial species in maternal placenta, amniotic fluid and meconium. The colonization of the human gut begins at birth with a rapid expansion of bacterial diversity and is characterized by a successively changing composition that eventually becomes relatively stable in adulthood. While the specific microbial species and subspecies and their proportions vary greatly from person to person the individual microbiome is unique and becomes more diverse in the elderly.

Important factors for the composition of the intestinal microbial community are endogenous and exogenous factors. Examples are mode of delivery of the neonates, diet (dietary supplements, breast-feeding, formula-feeding), xenobiotics, including antibiotics and other drugs. Further, infections and exposure to environmental microbial agents are established risk factors for childhood diseases, such as obesity and allergy [8]. Recent evidence further suggests that human genetic variation also influences the abundance of specific members of the intestinal microbial community.

Taken together, the emerging data suggest that the detailed characterization of the human in-

testinal microbiome composition, function and variation across different body sites will reveal important commensal host-microbe as well as microbe-, microbe interactions that may play a role in human health and disease.

In view of the numerous and diverse physiological functions of the intestinal microbiota in human health (Table 1) it is not surprising that it is also involved in gastrointestinal as well as non-gastrointestinal diseases, such as obesity/metabolic syndrome, and atherosclerosis/cardiovascular as well as neurologic/psychiatric diseases, making it one of the most dynamic current topics in biomedical research (Table 2). In the following, a few examples will be discussed in more detail.

### 2.2.1. Inflammatory bowel diseases and colon cancer

The inflammatory bowel diseases (IBD) in humans include ulcerative colitis (UC) and Crohn disease (CD). These are characterized by inflammation limited to the mucosal layer of the colon in UC and the transmural involvement of the gastrointestinal tract, including extraintestinal sites in CD. While the pathogenesis of IBD is not fully understood, it is clear that its pathology depends among others on the intestinal microbial community. Further, a case-control study identified “IBD-specific” alterations of the intestinal microbiota that may serve as biomarkers for the prediction of disease predisposition, activity/severity and responsiveness to therapy.

The three components – environment, host genetics and the microbial community – interact to maintain homeostasis in the intestine. The disruption of the stability of this interaction may be a trigger for disease development. Two recent publications shed a new light on the pathogenesis of IBD through the change of the intestinal microbial composition involving two different pathways: helminth infection [9] and lipocalin-2 expression [10], respectively.

*Helminth infection, microbial community and IBD.* Epidemiologic studies demonstrated a major increase of the incidence of IBD in the developed world, suggesting a change in the environment, including an alteration of the intestinal microbiome and a decreased exposure to intestinal parasites, such as helminths. In mice deficient for the CD susceptibility gene *Nod2* (*Nod2*<sup>-/-</sup> knockout) [11] it could be demonstrated that small intestinal abnormalities develop in the face of a sustained colonization with the inflammatory bacterium *Bacteroides vulgatus*, an ubiquitous member of the intestinal microbial community. Chronic infection of *Nod2*<sup>-/-</sup> mice with the parasitic worm *Trichuris muris*, however, inhibited colonization with inflammatory *Bacteroides* species and promoted the establishment of a protective microbial environment enriched in *Clostridiales* [9]. Further, the authors demonstrated that individuals from helminth-endemic regions harbour a similar protective microbial community and deworming treatment reduced *Clostridiales* and increased *Bacteroidales*, resulting in an increased IBD incidence. These data support the “hygiene hypothesis” whereby certain individuals are genetically susceptible to the consequences of a changing intestinal microbial community that favors IBD development.

*Lipocalin-2 protection from IBD and colon cancer.* Lipocalin-2 (*Lcn2*) is an antimicrobial peptide with high mucosal and fecal concentrations in patients with IBD. It is produced by various cell types, including epithelial cells, and acts as an antimicrobial defense mediator by binding to a subset of bacterial siderophores, thereby preventing bacterial iron acquisition and growth of siderophore-dependent strains. While it has been implicated in several biologic processes, such as acute phase response, erythropoiesis and iron metabolism, its functional role in contributing to IBD development remained unclear.

To decipher the role of *Lcn2* in colon inflammation, mice double deficient in *Lcn2* and IL-10 (*Lcn2*<sup>-/-</sup>/*IL10*<sup>-/-</sup> double knockout) were generated and compared to single knockouts and wild-type animals. The experimental data indicate that *Lcn2* expression protects from early onset colitis and the spontaneous emergence of right-sided colonic tumors that result from IL-10 deficiency. The inflammation is driven by IL-6 which also controls tumorigenesis. The *Lcn2*<sup>-/-</sup>/*IL10*<sup>-/-</sup> double knockout mice showed major alterations of their intestinal microbial community, especially with respect to the facultative pathogenic *Alistipes* spp. These contribute to inflammation and tumorigenesis as shown by the transmissibility of the phenotype and the protection by antibiotic therapy. Taken together, the authors demonstrate that *Lcn2* protects against intestinal inflammation and tumorigenesis in the face of an altered intestinal microbial composition [10].

Recently, it was discovered that the probiotic *Lactobacillus casei* strain ATCC 334 produces ferrichrome that inhibits colon cancer progression by apoptosis mediated through the c-Jun N-terminal kinase pathway [12], possibly representing a novel tumor-suppressing strategy.

### 2.2.2. Obesity

Obesity [13], insulin resistance [14] and kwashiorkor [15] are examples for which a correlation between microbial dysbiosis and the clinical state has been demonstrated. Further, in genetically susceptible hosts, the transplantation of fecal microbiota from healthy donors to patients resulted in clinical improvement. The underlying concept is a “common ground hypothesis” that involves a leaky mucosa caused by various endogenous or exogenous factors, the expansion of opportunistic microbes (dysbiotic pathobionts) with the generation of pathogenic microbial gene products which can be transferred to genetically susceptible individuals [6].

### 2.2.3. Atherosclerosis and thrombosis risk

Recent studies suggest that intestinal microbes are involved in atherosclerosis. In this context, foods rich in choline, phosphatidylcholine and carnitines such as meat, egg yolk and high-fat dairy products, serve as precursors of trimethylamine (TMA) and TMA N-oxide (TMAO) that accelerates atherosclerosis and elevated TMAO blood levels are associated with an increased risk for atherosclerotic heart disease and incident major adverse cardiac events. Further, TMAO enhances platelet hyperreactivity and thrombotic events in studies of animal model, employing dietary choline or TMAO, germ-free mice and microbial transplantation, collectively confirming the key role of intestinal microbiota [16]. Taken together, these results reveal a previously unknown link between specific dietary nutrients, intestinal microbes and atherosclerosis/thrombosis risk (Fig. 1).

The intestinal TMAO formation is a two-step process involving the generation of TMA by intestinal microbes after food ingestion and the hepatic conversion of TMA to TMAO by host flavin monooxygenases. In a recent, study Wang et al. [17] demonstrated that 3,3-dimethyl-1-butanol (DMB), a structural analog of choline, blocks the intestinal TMA formation through the inhibition of the microbial TMA lyase, and results in reduced TMAO levels. Thus, “drugging the microbiome” with DMB may be a novel approach for the prevention/treatment of atherosclerosis (Fig. 2).

### 2.2.4. Neurodevelopmental, psychiatric and neurodegenerative diseases

Studies investigating the intestinal microbial-brain communication (gut-brain axis) demonstrate a critical role of the intestinal microbial community in modulating the maturation and function of tissue-resident immune cells in the central nervous system (CNS) as well as the activation of peripheral immune cells involved in neuroinflammation, brain injury, autoimmunity and neurogenesis [18]. Germ-free mice raised under sterile conditions or mice depleted of their intestinal microbiota by antibiotics show major alterations in behaviours or neuropathologies that characterize neurodevelopmental, psychiatric and neurodegenerative disorders. These include among others autism spectrum disorders, depression and Alzheimer’s or Parkinson’s disease (Table 2).

An impressive example for a pathogenic role of the intestinal microbial community is Parkinson’s disease (PD). In patients with PD, plaques in brain cells as well as in the intestine containing the neurotoxic protein alpha-synuclein (AS) are a hallmark of the disease. For example, in PD patients gastric motility is frequently impaired and AS levels in the intestine are elevated.

In an animal model, mice over expressing AS indeed develop neurologic deficits resembling those of patients with PD. Recently, three lines of evidence demonstrated a central role of the intestinal microbial community in the pathogenesis of PD (Fig. 3): (1) in the PD mouse model germ-free animals developed fewer plaques and almost no neurological deficits as compared to conventionally colonized controls, (2) treatment of PD mice with antibiotics resulted in an improvement of the neurological deficits and (3) fecal transplantation from patients with PD to germ-free mice resulted in neurological deficits resembling PD [19].

The underlying concept is the central contribution of the microbial community to a defect of the microglia *via* short-chain fatty acids (SCFAs) that represent bacterial fermentation products. While germ-free mice showed a reduced microglia mice, SCFAs modulate microglia and enhance PD pathophysiology [19]. The identification of the disease-causing bacteria and the mechanism leading to the deposition of the neurotoxic AS plaques await further clarification.

### 3. Conclusions and Perspectives

Basic biomedical research has made major advances in recent years and holds the promise to increasingly provide individual diagnostic, preventive as well as therapeutic options for patients with inherited or acquired, malignant or non-malignant diseases. Apart from an increasing number of host genetic susceptibility loci and environmental factors, the individual microbial community is central for the barrier between microbes and hosts. In particular, the intestinal microbial community is involved in a large number of normal biological functions in health (Table 1) as well as in numerous common, gastrointestinal and non-gastrointestinal diseases, such as obesity/metabolic syndrome, atherosclerosis/thrombosis or neurodevelopmental, psychiatric and neurodegenerative diseases (Table 2). Dietary interventions targeting intestinal microbiota, such as calory restricted diets rich in fiber and vegetables as well as fecal microbial transplantation are examples for health benefits in humans. In recent years, the intestinal microbiome thus has become one of the most dynamic areas of biomedical research that holds an enormous potential for interventions regarding human health and disease.

Table 1

Functions of the intestinal microbial community in human health (examples)

	References
<b>Host Physiology</b>	
Adaptive immunity	[20]
Autoimmunity	[21]
Innate immunity	[22]
Cell proliferation	[23]
Bone density	[24]
Vascularization	[25]
Neurological signalling	[26]
<b>Biosynthesis</b>	
Neurotransmitters	
Steroid hormones	
Vitamins	
<b>Metabolism</b>	
Dietary components	
Bile salts	
Drugs	
Xenobiotics	

Table 2

Disease associations with the intestinal microbial community (examples)

<b>Allergies / Allergy protection</b>
<b>Atherosclerosis / Thrombosis / Cardiovascular Disease</b>
<b>Cancer</b>
<b>Diabetes mellitus</b>
<b>Immune-Mediated Inflammatory Diseases</b>
– Inflammatory bowel diseases
– Multiple sclerosis
– Rheumatoid arthritis
– Psoriasis
<b>Kwashiorkor</b>
<b>Liver Diseases</b>
<b>Metabolic Syndrome / Obesity</b>
<b>Neurodevelopmental, psychiatric and neurodegenerative diseases</b>
– Autism
– Depression
– Alzheimer's Disease, Parkinson's Disease




Fig. 1. The intestinal microbial metabolite trimethylamine (TMA) and the atherosclerosis/thrombosis risk [16]




Fig. 2. Inhibition of intestinal microbial trimethylamine (TMA) synthesis by 3,3-dimethyl-1-butanol (DMB) and attenuation of atherosclerosis [17]




Fig. 3. Contribution of short chain fatty acids (SCFA) and fecaltransplantation from patients with Parkinson's disease (PD) to PD pathogenesis and its prevention by elimination of the intestinal microbiota [19]

### Acknowledgement

*The excellent secretarial assistance of Mrs. Mariette Gutzsell is gratefully acknowledged.*

### Conflict of interests

*The author declares no conflict of interest.*

### Financial disclosure

*The author has no financing to disclose.*

### References:

1. Manolio T.A., Collins F.S. The HapMap and genome-wide association studies in diagnosis and therapy // *Annu. Rev. Med.* 2009. No. 60. P. 443–456.
2. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study / L. Hou, U. Heilbronner, F. Degenhardt, M. Adli, K. Akiyama, N. Akula [et al.] // *Lancet*. 2016. March 12. P. 1085–1093. doi:10.1016/S0140-6736(16)00143-4.
3. Human Microbiome Project C. A framework for human microbiome research // *Nature*. 2012. No. 486. P. 215–221.
4. Morgan X.C., Segata N., Huttenhower C. Biodiversity and functional genomics in the human microbiome // *Trends Genet.* 2013. No. 29. P. 51–58.
5. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis // N.G. Rossen, S. Fuentes, M.J. van der Spek, J.G. Tijssen, J.H. Hartman, A. Duflo [et al.] // *Gastroenterology*. 2015. No. 149. P. 110–8 e4.

### Примечания:

1. Manolio T.A., Collins F.S. The HapMap and genome-wide association studies in diagnosis and therapy // *Annu. Rev. Med.* 2009. No. 60. P. 443–456.
2. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study / L. Hou, U. Heilbronner, F. Degenhardt, M. Adli, K. Akiyama, N. Akula [et al.] // *Lancet*. 2016. March 12. P. 1085–1093. doi:10.1016/S0140-6736(16)00143-4.
3. Human Microbiome Project C. A framework for human microbiome research // *Nature*. 2012. No. 486. P. 215–221.
4. Morgan X.C., Segata N., Huttenhower C. Biodiversity and functional genomics in the human microbiome // *Trends Genet.* 2013. No. 29. P. 51–58.
5. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis // N.G. Rossen, S. Fuentes, M.J. van der Spek, J.G. Tijssen, J.H. Hartman, A. Duflo [et al.] // *Gastroenterology*. 2015. No. 149. P. 110–8 e4.



6. Lynch S.V., Pedersen O. The Human Intestinal Microbiome in Health and Disease // *N. Engl. J. Med.* 2016. No. 375. P. 2369–2379.
7. An integrated catalog of reference genes in the human gut microbiome / J. Li, H. Jia, X. Cai, H. Zhong, Q. Feng, S. Sunagawa [et al.] // *Nat. Biotechnol.* 2014. No. 32. P. 834–841.
8. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation // K.E. Fujimura, A.R. Sitarik, S. Havstad, D.L. Lin, S. Levan, D. Fadrosh [et al.] // *Nat. Med.* 2016. No. 22. P. 1187–1191.
9. Helminth infection promotes colonization resistance via type 2 immunity / D. Ramanan, R. Bowcutt, S.C. Lee, M.S. Tang, Z.D. Kurtz, Y. Ding [et al.] // *Science.* 2016. No. 352. P. 608–612.
10. Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations / A.R. Moschen, R.R. Gerner, J. Wang, V. Klepsch, T.E. Adolph, S.J. Reider [et al.] // *Cell Host Microbe.* 2016. No. 19. P. 455–469.
11. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study / I. Cleynen, G. Boucher, L. Jostins, L.P. Schumm, S. Zeissig, T. Ahmad [et al.] // *Lancet.* 2016. No. 387. P. 156–167.
12. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis / H. Konishi, M. Fujiya, H. Tanaka, N. Ueno, K. Moriichi, J. Sasajima [et al.] // *Nature Communications.* 2016. No. 7. P. 12365.
13. Gut microbiota from twins discordant for obesity modulate metabolism in mice / V.K. Ridaura, J.J. Faith, F.E. Rey, J. Cheng, A.E. Duncan, A.L. Kau [et al.] // *Science.* 2013. 341. P. 1241214.
14. Human gut microbes impact host serum metabolome and insulin sensitivity / H.K. Pedersen, V. Gudmundsdottir, H.B. Nielsen, T. Hyotylainen, T. Nielsen, B.A. Jensen [et al.] // *Nature.* 2016. No. 535. P. 376–381.
15. Persistent gut microbiota immaturity in malnourished Bangladeshi children / S. Subramanian, S. Huq, T. Yatsunenko, R. Haque, M. Mahfuz, M.A. Alam [et al.] // *Nature.* 2014. No. 510. P. 417–421.
16. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk / W. Zhu, J.C. Gregory, E. Org, J.A. Buffa, N. Gupta, Z. Wang [et al.] // *Cell.* 2016. No. 165. P. 111–124.
17. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis / Z. Wang, A.B. Roberts, J.A. Buffa, B.S. Levison, W. Zhu, E. Org [et al.] // *Cell.* 2015. No. 163. P. 1585–1595.
18. Fung T.C., Olson C.A., Hsiao E.Y. Interactions between the microbiota, immune and nervous systems in health and disease // *Nature Neuroscience.* 2017. No. 20. 145–155.
19. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease / T.R. Sampson, J.W. Debelius, T. Thron, S. Janssen, G.G. Shastri, Z.E. Ilhan [et al.] // *Cell.* 2016. No. 167. P. 1469–1480 e12.
20. Honda K., Littman D.R. The microbiota in adaptive immune homeostasis and disease // *Nature.* 2016. No. 535. P. 75–84.
6. Lynch S.V., Pedersen O. The Human Intestinal Microbiome in Health and Disease // *N. Engl. J. Med.* 2016. No. 375. P. 2369–2379.
7. An integrated catalog of reference genes in the human gut microbiome / J. Li, H. Jia, X. Cai, H. Zhong, Q. Feng, S. Sunagawa [et al.] // *Nat. Biotechnol.* 2014. No. 32. P. 834–841.
8. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation // K.E. Fujimura, A.R. Sitarik, S. Havstad, D.L. Lin, S. Levan, D. Fadrosh [et al.] // *Nat. Med.* 2016. No. 22. P. 1187–1191.
9. Helminth infection promotes colonization resistance via type 2 immunity / D. Ramanan, R. Bowcutt, S.C. Lee, M.S. Tang, Z.D. Kurtz, Y. Ding [et al.] // *Science.* 2016. No. 352. P. 608–612.
10. Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations / A.R. Moschen, R.R. Gerner, J. Wang, V. Klepsch, T.E. Adolph, S.J. Reider [et al.] // *Cell Host Microbe.* 2016. No. 19. P. 455–469.
11. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study / I. Cleynen, G. Boucher, L. Jostins, L.P. Schumm, S. Zeissig, T. Ahmad [et al.] // *Lancet.* 2016. No. 387. P. 156–167.
12. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis / H. Konishi, M. Fujiya, H. Tanaka, N. Ueno, K. Moriichi, J. Sasajima [et al.] // *Nature Communications.* 2016. No. 7. P. 12365.
13. Gut microbiota from twins discordant for obesity modulate metabolism in mice / V.K. Ridaura, J.J. Faith, F.E. Rey, J. Cheng, A.E. Duncan, A.L. Kau [et al.] // *Science.* 2013. 341. P. 1241214.
14. Human gut microbes impact host serum metabolome and insulin sensitivity / H.K. Pedersen, V. Gudmundsdottir, H.B. Nielsen, T. Hyotylainen, T. Nielsen, B.A. Jensen [et al.] // *Nature.* 2016. No. 535. P. 376–381.
15. Persistent gut microbiota immaturity in malnourished Bangladeshi children / S. Subramanian, S. Huq, T. Yatsunenko, R. Haque, M. Mahfuz, M.A. Alam [et al.] // *Nature.* 2014. No. 510. P. 417–421.
16. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk / W. Zhu, J.C. Gregory, E. Org, J.A. Buffa, N. Gupta, Z. Wang [et al.] // *Cell.* 2016. No. 165. P. 111–124.
17. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis / Z. Wang, A.B. Roberts, J.A. Buffa, B.S. Levison, W. Zhu, E. Org [et al.] // *Cell.* 2015. No. 163. P. 1585–1595.
18. Fung T.C., Olson C.A., Hsiao E.Y. Interactions between the microbiota, immune and nervous systems in health and disease // *Nature Neuroscience.* 2017. No. 20. 145–155.
19. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease / T.R. Sampson, J.W. Debelius, T. Thron, S. Janssen, G.G. Shastri, Z.E. Ilhan [et al.] // *Cell.* 2016. No. 167. P. 1469–1480 e12.
20. Honda K., Littman D.R. The microbiota in adaptive immune homeostasis and disease // *Nature.* 2016. No. 535. P. 75–84.



21. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans / T. Vatanen, A.D. Kostic, E. d’Hennezel, H. Siljander, E.A. Franzosa, M. Yassour [et al.] // *Cell*. 2016. No. 165. P. 842–853.
22. The microbiome and innate immunity / C.A. Thaiss, N. Zmora, M. Levy, E. Elinav // *Nature*. 2016. No. 535. P. 65–74.
23. Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon / N. Ijssennagger, C. Belzer, G.J. Hooiveld, J. Dekker, S.W. van Mil, M. Muller [et al.] // *Proc. Natl. Acad. Sci. USA*. 2015. No. 112. P. 10038–10043.
24. Antibiotics in early life alter the murine colonic microbiome and adiposity / I. Cho, S. Yamanishi, L. Cox, B.A. Methe, J. Zavadil, K. Li [et al.] // *Nature*. 2012. No. 488. P. 621–626.
25. Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodeling / C. Reinhardt, M. Bergentall, T.U. Greiner, F. Schaffner, G. Ostergren-Lunden, L.C. Petersen [et al.] // *Nature*. 2012. No. 483. P. 627–631.
26. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis / J.M. Yano, K. Yu, G.P. Donaldson, G.G. Shastri, P. Ann, L. Ma [et al.] // *Cell*. 2015. No. 161. P. 264–276.
21. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans / T. Vatanen, A.D. Kostic, E. d’Hennezel, H. Siljander, E.A. Franzosa, M. Yassour [et al.] // *Cell*. 2016. No. 165. P. 842–853.
22. The microbiome and innate immunity / C.A. Thaiss, N. Zmora, M. Levy, E. Elinav // *Nature*. 2016. No. 535. P. 65–74.
23. Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon / N. Ijssennagger, C. Belzer, G.J. Hooiveld, J. Dekker, S.W. van Mil, M. Muller [et al.] // *Proc. Natl. Acad. Sci. USA*. 2015. No. 112. P. 10038–10043.
24. Antibiotics in early life alter the murine colonic microbiome and adiposity / I. Cho, S. Yamanishi, L. Cox, B.A. Methe, J. Zavadil, K. Li [et al.] // *Nature*. 2012. No. 488. P. 621–626.
25. Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodeling / C. Reinhardt, M. Bergentall, T.U. Greiner, F. Schaffner, G. Ostergren-Lunden, L.C. Petersen [et al.] // *Nature*. 2012. No. 483. P. 627–631.
26. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis / J.M. Yano, K. Yu, G.P. Donaldson, G.G. Shastri, P. Ann, L. Ma [et al.] // *Cell*. 2015. No. 161. P. 264–276.